Biologics and biosimilars researchers from around the globe will gather for the 7th European Biosimilars Congress 2017 in Munich between
May 15-17.

The congress will bring together everyone from scientists, researchers and business development managers to CEOs, directors, IP Attorneys and Regulatory Officials. Themes due for discussion will include how biosimilar product development can deliver safe and efficacious biologic products to the market, how emerging biologics are helping patients with psoriasis, rheumatic arthritis, certain cancers, inflammatory bowel disease and how emerging biosimilar insulins are likely to become more important as patents for major branded insulin products start to expire in the next few years.

Other themes will include how regulation impacts on the biosimilars market and what effect Brexit will have on the industry. More information is available at